Codexis, Inc.

Arrowhead Pharmaceuticals, Inc.

Otsuka America Pharmaceutical, Inc.

Neurovance, Inc.

Merck Sharp + Dohme Corp.

Fred J Fleitz

Emily Mundorff

Christopher K Savile

Paul N Devine

Gregory Hughes

John Limanto

Brendan T Grau

Valeriya N Smolenskaya

Anthony Alexander McKinney

David Alan Engers

Venkat Kusukuntla

Yonglai Yang

Walter Piskorski

Franklin Bymaster

Tao Pei

Zhen Li

David B Rozema

Darren H Wakefield

Andrei V Blokhin

Agnieszka Glebocka

Jonathan D Benson

Michael Shawn Lawler

Erich Altenhofer

Pankaj Kumar

Jingjun Yin

Ian Mangion

Valeriya Smolenskaya

Anthony Alexander Mckinney

Brendon T Grau

The present disclosure relates to methods of using transaminase polypeptides in the synthesis of chiral amines from prochiral ketones.

Transaminase reactions

Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.

Targeting ligands for therapeutic compounds

The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.

Crystalline compounds

Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to a therapeutic compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.

Targeting ligands

The present invention is directed to processes for preparing an intermediate for a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

Process for the preparation of an intermediate for an orexin receptor antagonist

Growing community of inventors

Germantown, WI, United States of America

Fred J Fleitz